Advertisement

Annals of Hematology

, Volume 84, Issue 5, pp 282–286 | Cite as

Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease

  • J. B. SchnogEmail author
  • T. Teerlink
  • F. P. L. van der Dijs
  • A. J. Duits
  • F. A. J. Muskiet
  • CURAMA study group
Original Article

Abstract

In recent years an important role has been ascribed to a reduced nitric oxide (NO) availability in the pathophysiology of sickle cell disease (SCD). Endogenously produced inhibitors of NO synthase, in particular asymmetric dimethylarginine (ADMA), are currently considered of importance in various vascular disease states characterized by reduced NO availability. We determined ADMA levels in plasma of 12 adult sickle cell patients (eight HbSS and four HbSC), and compared these to plasma levels in race- and age-matched controls. Sickle cell patients were characterized by strongly elevated levels of ADMA [HbSS: median 0.63 μmol/l (interquartile range 0.54–0.85), HbSC: 0.43 μmol/l (0.40–0.46), HbAA: 0.33 μmol/l (0.32–0.35) p<0.001]. ADMA levels were highest in HbSS patients with lowest hemoglobin levels and highest leukocyte counts, and in HbSS patients ADMA levels were positively associated with serum levels of soluble vascular cell adhesion molecule-1. These results suggest an important role of ADMA in limiting NO availability in SCD, and its role in the pathophysiology of SCD should be further investigated.

Keywords

Sickle cell disease Arginine Nitric oxide Asymmetric dimethylarginine (ADMA) Hemolysis Endothelium 

References

  1. 1.
    Serjeant GR (1997) Sickle-cell disease. Lancet 350:725–730CrossRefPubMedGoogle Scholar
  2. 2.
    Schnog JB, Lard LR, Rojer RA, van der Dijs FP, Muskiet FA, Duits AJ (1998) New concepts in assessing sickle cell disease severity. Am J Hematol 58:61–66CrossRefPubMedGoogle Scholar
  3. 3.
    Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115:721–728CrossRefPubMedGoogle Scholar
  4. 4.
    Makis AC, Hatzimichael EC, Bourantas KL (2000) The role of cytokines in sickle cell disease. Ann Hematol 79:407–413CrossRefPubMedGoogle Scholar
  5. 5.
    Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101–106CrossRefPubMedGoogle Scholar
  6. 6.
    Wun T (2001) The role of inflammation and leukocytes in the pathogenesis of sickle cell disease; haemoglobinopathy. Hematology 5:403–412PubMedGoogle Scholar
  7. 7.
    Reiter CD, Gladwin MT (2003) An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 10:99–107CrossRefPubMedGoogle Scholar
  8. 8.
    Hallemeesch MM, Lamers WH, Deutz NE (2002) Reduced arginine availability and nitric oxide production. Clin Nutr 21:273–279CrossRefPubMedGoogle Scholar
  9. 9.
    Morris CR, Morris Jr SM, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP (2003) Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168:63–69CrossRefPubMedGoogle Scholar
  10. 10.
    Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, Schechter AN, Gladwin MT (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389CrossRefPubMedGoogle Scholar
  11. 11.
    Schnog JB, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FAJ (2004) Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 83:371–375CrossRefPubMedGoogle Scholar
  12. 12.
    Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350:886–895CrossRefPubMedGoogle Scholar
  13. 13.
    Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24:1023–1030CrossRefPubMedGoogle Scholar
  14. 14.
    Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108:1493–1498CrossRefPubMedGoogle Scholar
  15. 15.
    Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141–1146PubMedGoogle Scholar
  16. 16.
    Yoo JH, Lee SC (2001) Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158:425–430CrossRefPubMedGoogle Scholar
  17. 17.
    Nijveldt RJ, Teerlink T, van Leeuwen PA (2003) The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 22:99–104CrossRefPubMedGoogle Scholar
  18. 18.
    Moshage H, Kok B, Huizenga JR, Jansen PL (1995) Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41:892–896PubMedGoogle Scholar
  19. 19.
    Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303:131–137CrossRefPubMedGoogle Scholar
  20. 20.
    Tran CT, Leiper JM, Vallance P (2003) The DDAH/ADMA/NOS pathway. Atherosclerosis Suppl 4:33–40CrossRefGoogle Scholar
  21. 21.
    Sydow K, Munzel T (2003) ADMA and oxidative stress. Atherosclerosis Suppl 4:41–51CrossRefGoogle Scholar
  22. 22.
    Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572–575CrossRefPubMedGoogle Scholar
  23. 23.
    Goonasekera CD, Shah V, Rees DD, Dillon MJ (2000) Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press 9:16–21CrossRefPubMedGoogle Scholar
  24. 24.
    Stuart MJ, Setty BN (1999) Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 94:1555–1560PubMedGoogle Scholar
  25. 25.
    Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644CrossRefPubMedGoogle Scholar
  26. 26.
    Schnog JB, Mac Gillavry MR, Van Zanten AP, Meijers JC, Rojer RA, Duits AJ, ten Cate H, Brandjes DPM (2004) Protein C and S and inflammation in sickle cell disease. Am J Hematol 76:26–32CrossRefPubMedGoogle Scholar
  27. 27.
    Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84:643–649PubMedGoogle Scholar
  28. 28.
    Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR (2000) Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342:83–89CrossRefPubMedGoogle Scholar
  29. 29.
    Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM (1998) Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91:288–294PubMedGoogle Scholar
  30. 30.
    Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR (1991) Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325:11–16PubMedGoogle Scholar
  31. 31.
    Schnog JB, Rojer RA, Mac Gillavry MR, ten Cate H, Brandjes DP, Duits AJ (2003) Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol 82:109–113PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • J. B. Schnog
    • 1
    • 2
    • 6
    Email author
  • T. Teerlink
    • 3
  • F. P. L. van der Dijs
    • 4
  • A. J. Duits
    • 2
  • F. A. J. Muskiet
    • 5
  • CURAMA study group
  1. 1.Department of Internal MedicineSlotervaart HospitalAmsterdamThe Netherlands
  2. 2.Red Cross Blood Bank FoundationCuraçaoNetherlands Antilles
  3. 3.Department of Clinical ChemistryVU University Medical CenterAmsterdamThe Netherlands
  4. 4.Department of Clinical ChemistryMC Haaglanden-WesteindeThe HagueThe Netherlands
  5. 5.Department of Pathology and Laboratory MedicineGroningen University HospitalGroningenThe Netherlands
  6. 6.Department of Internal Medicine (9B)AmsterdamThe Netherlands

Personalised recommendations